ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 385

The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis – There Is Need for Guidelines

A. Bharadwaj1 and Carol Alves2, 1Rheumatology, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom, 2Research & Development, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), steroids and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which causes significant pain and swelling in the joints. The early treatment of the disease mainly rests on two groups of agents; Disease modifying drugs and Corticosteroids. Steroids are very effective for the treatment of early disease, acutely controlling the disease activity and reducing the long-term damage  They are used both as systemically (Oral or Intramuscular) or locally, however there is no consensus on the required dose, route of administration or duration of use in this condition.

The published data about adverse events of steroid usage in this situation is not clear and there is suggestion that quick aggressive control of inflammatory disease may actually outweigh the risk of damage. 

Methods:

A questionnaire was sent by post to all consultant Rheumatologists in England under ‘Freedom of Information act (FOI)’ to 131 NHS trusts.  Questions were aimed to enquire about the initial steroid regime used by consultant rheumatologists in adult cases (≥ 18 yrs) of confirmed RA.   The responses were received back by post and analysed.

Results:

Total response received were 130 (92 % response rate), with 82.4 % agreeing on the early routine use of steroids in their practice.  53.6% used the Oral route, 48% used the intramuscular (IM) route and 45.6% of Consultants used the intra-articular route (either alone or in combination with other routes). 

For those who used oral Prednisolone, the initial starting dose varied from 60mg (6.3%) to 7.5 mg (11.1% responses) per day with the majority using an initial dose of 15 mg (25.3%) or 20mg (23.8%) daily.

The duration of oral steroid use varied from 1 month (4.2%) to 2 yrs (4.2%) with the majority being for 4-6 months (72.3%).

The dose of IM Depomedrone varied from 40mg – 160 mg, with majority using 120 mg (86.2%), for a total duration that again varied from 2 months to 2 years, with the majority being 6 months (52.2%). 

The dose of intraarticular injection for large joint also varied from 20 mg to 60 mg of Depomedrone with 40 mg used by majority (92%) of rheumatologist.

Conclusion:

Majority of Rheumatologist use steroids for initial treatment of early Rheumatoid Arthritis.  There is a wide variability in the use of steroids including its route, dose and duration of use.  There is therefore an urgent need of scientifically proved guidelines on their initial use.


Disclosure:

A. Bharadwaj,
None;

C. Alves,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-wide-variation-in-corticosteroid-use-in-early-rheumatoid-arthritis-there-is-need-for-guidelines/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology